Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...

STRIDE investigator Marc Bonaca, MD, MPH, University of Colorado School of Medicine, highlights how the data could provide insight into peripheral artery disease and type 2 diabetes treatment options.

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

People taking an oral formulation of the glucagon-like peptide-1 (GLP-1) agonist semaglutide were 14% less likely than those taking a placebo to ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

A Medicine study used artificial intelligence to discover a naturally occurring molecule, specifically, a peptide, that ...

MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025.

A new clinical trial suggests that semaglutide — the active ingredient in the widely used drugs Ozempic and Wegovy — may help ...

Taking medications like Ozempic and Wegovy may lead to more hair loss than other weight loss drugs, new research found.

Mounjaro, a weight loss drug launched by Eli Lilly in India, could be a game-changer and has been making waves lately. Here's ...